Navigation Links
Timing May Matter in Organ Donation Decisions
Date:4/22/2009

Study highlights importance of a gap between bad news and request

WEDNESDAY, April 22 (HealthDay News) -- Whether a family decides to donate -- or not donate -- a dying relative's organs depends on many things, but who makes the request and when it's made are key, U.K. researchers have found.

A request for organ donation should not take place at the same time that relatives are told their loved one has died or when brain stem testing takes place, concluded Dr. Duncan Young, of John Radcliffe Hospital in Oxford, and his research colleagues. Their review of 20 studies found that it's important that there be a time gap between giving relatives bad news and making an organ donation request.

They also found that it's best if the transplant request is made by a transplant coordinator together with hospital staff.

Other important factors that influence relatives' decision to consent to organ donation include:

  • The amount of information they're given
  • How the relatives perceive the quality of care given to their loved one
  • Their understanding of what brain stem death actually means
  • The setting where the request takes place, with a private location deemed best
  • The approach and expertise of the person making the request
  • The amount of time families have to consider the request

The findings may not be surprising, the researchers said, but implementing them might increase organ donation rates and save more lives. Their findings appear online in the BMJ.

Teresa Shafer, of the LifeGift Organ Donation Center in Texas, wrote in an accompanying editorial that requesting an organ donation involves more than simply "popping the question." She described it as a "process consisting of observation, collaboration, planning and action that is based on family and hospital dynamics."

Hospitals and organ procurement groups must work togeth
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call
2. T cell immunity enhanced by timing of interleukin-7 therapy
3. AUDIO from Medialink and AXA Equitable: Timing Retirement Thinking
4. Appropriate timing in the use of breast shields in children can further reduce MDCT radiation dose
5. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
6. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
7. When It Comes to Pregnancy, Timing Is Everything
8. Timing of HRT May Influence Heart Risks
9. Research shows timing improves cleft palate surgery
10. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
11. A new breakthrough in timing of urgent endoscopy for gastrointestinal bleeding patients

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Timing May Matter in Organ Donation Decisions
Timing May Matter in Organ Donation Decisions
(Date:11/24/2009)...Researchers at Ben-Gurion University of the Negev ... skin tumors, including melanomas that aren,t visi...the OSPI instrument (Optical Spectro-Polarimetric ...e never been seen before - including melanoma in p...ns and were awaiting surgery for their removal. Th...
(Date:11/24/2009)...Mid-Winter Meetings Jan. 27Feb. 2, 2010, at the Al...his year, SNM joins its annual Mid-Winter Educatio...cational Symposium of the American College of Nucl...r Imaging Summit and the Clinical Trials Network C...icipants an outstanding range of scientific conten...
(Date:11/24/2009)...sed sevenfold, study finds, , , TUESDAY...c-resistant infections normally found in the commu...tpatients, raising the risk that inpatients could ... to 2006, researchers found a sevenfold increase i...sistant Staphylococcus aureus (MRSA) infections....
(Date:11/24/2009)...ice to be coupled with Stem Cell Therapy. , ...24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB... a manufacturer of lasers regarding the developmen...ed by Entest and used in conjunction with several ...ntest. These therapies are aimed at increasing eff...
(Date:11/24/2009)...o Get a Leg Up From the American Podiatric Medical...Md. (Vocus) November 24, 2009 -- The average perso... that number dramatically increases during the hol...continue making their holiday travel plans, it&rsq...runt of aches and pains while on the road. , , , ...
Breaking Medicine News(10 mins):Health News:New device enables early detection of cancerous skin tumors -- Ben Gurion U. 2Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Keep Holiday Travel Foot-Friendly 2Health News:Keep Holiday Travel Foot-Friendly 3
...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...
...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...
...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...
...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...
...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...
... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...
Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
(Date:11/24/2009)...,Nov.24/PRNewswire-Asia/--HuifengBio-Pharmaceutica...eveloperandproducer,ofplantextractsandpharmaceutic...landfoodproductioninXi,an,China,todayreportedthati...revenues. , RevenuesforthequarterendedSept.30...om$3,534,623forthesamequarterin2008.Netincome,amou...
(Date:11/24/2009)...OOD,Calif.,Nov.24/PRNewswire-FirstCall/--IPCTheHos...alhospitalistphysiciangrouppracticecompany,announc...t,wasnamedby ACPHospitalist asoneofthe2009TopTenHo...2009issueofthemagazine. ,, Dr.Vaidyanhasbeenapr...vesasdirectorofhospitalmedicineatSt.Mary,sHealthCe...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--ZimmerHoldings,Inc....atinginthe21stAnnualPiperJaffrayHealthCareConferen...ternTime. ,, Alivewebcastofthepresentationcanbe...://investor.zimmer.com .Thewebcastwillbearchivedfo...any ,, Foundedin1927andheadquarteredinWarsaw,I...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 1Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 3Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 1Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 2Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 4Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 5Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 6
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
Schepens Depressor 8.0mm Wide Tip Thimble Size 12
Yavitz Flap Cover
Chayett Drainage Ring
Weck-Cel Points
Medicine Products: